| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Prime Medicine, Inc.$3.78
-0.43 (-10.17%)
D 25Pipeline Score Richly Valued Biotech · Commercial
Market Cap
536.43 M
EPS
-1.25
P/E Ratio
-
Value Trade
10.58 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
34.10 M
Operating CF
-42.71 M
Total Assets
294.73 M
Total Liabilities
218.03 M
Equity
76.70 M
D/E Ratio
12,345
-3.57 %
Week
-22.25 %
1 Month
-9.45 %
3 Month
-17.5 %
6 Month
-84.34 %
5 Year
-84.34 %
All Time
Cash Data
Cash Position
135.50 M
Monthly Burn
14.24 M
Runway
7.6 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
6.65 M
52 Week Range
1.18 - 6.94
% held by Insiders
47.42 %
% held by Institutions
43.33 %
Enterprise Value
515.45 M
Total Shares
180.51 M
Short %
34.26 %
Float Shares
69.86 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Prime Medicine, Inc.
221Total events
11Upcoming
29Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 11
Event history 210
Jun 22, 2026
▲RMATPM359Designation
FDA granted RMAT designation for PM359
p47phox-deficient chronic granulomatous disease (CGD)source ↗
Jun 18, 2026
▲IND ClearancePM577aIND
New Zealand Medsafe clearance of Clinical Trial Application for PM577a
Wilson Disease (H1069Q mutation)source ↗
Jun 10, 2026
◆Oral PresentationPresentation
Prime Medicine CEO to present at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 4, 2026
◆Oral PresentationPresentation
Prime Medicine to present at Jefferies Global Healthcare Conference
Jun 2026
Jun 2026
◆IND SubmissionPM647IND
IND/CTA filing for PM647 in AATD
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
May 12, 2026
◆Oral PresentationPM577Presentation
Oral presentation at ASGCT 2026 on Wilson Disease program
Wilson Diseasesource ↗
Apr 16, 2026
Q2 2026
◆Trial InitiationPM577aTrial
Initiation of Phase 1/2 clinical trial expected
Wilson Disease (H1069Q mutation)source ↗
Drug Pipeline Intelligence
D25
Pipeline Score $8M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 25%
Micro Cap (rank 684 of 911)
Percentile RankPrime Medicine, Inc. faces pipeline headwinds (25/100), with $41M risk-adjusted pipeline value, led by PM359 in Chronic Granulomatous Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM359 Monoclonal antibody | Chronic Granulomatous Disease | Phase 1 | NCT06559176 | 56% | $41M | ENROLLING BY_INVITATION | 12 | AVERAGE | D (26) | Feb 1, 2030 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PM359 Fast TrackRMATOrphan+1 | chronic granulomatous disease | Phase 1/2 | 2025-12-08 | rapid neutrophil and platelet engraftment; durable restoration of NADPH oxidase activity; early clinical benefit Read More | Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease Read More | |
PM359 Fast TrackRMATOrphan+1 | chronic granulomatous disease | Phase 1/2 | 2025-12-08 | rapid neutrophil and platelet engraftment; durable restoration of NADPH oxidase activity; early clinical benefit Read More | Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease Read More | |
PM359 Fast TrackRMATOrphan+1 | chronic granulomatous disease | Phase 1/2 | 2025-12-08 | rapid neutrophil and platelet engraftment; durable restoration of NADPH oxidase activity; early clinical benefit Read More | Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRME
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRME Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRMEPrime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine has been granted RMAT designation by the FDA for PM359, an investigational therapy for chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, which indicates PM359's potential to significantly improve patient outcomes. The therapy is designed to address a critical unmet need in CGD, where treatment options are limited.
Read more →PRMEPrime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine has received clearance from New Zealand's Medsafe for its Clinical Trial Application for PM577a, targeting the H1069Q mutation in Wilson Disease. This marks the first clinical authorization for an in vivo Prime Editing therapy. The Phase 1/2 trial is set to begin in late 2026, with initial data expected in 2027, aiming to provide a one-time curative option for patients.
Read more →PRMEPrime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine, Inc. will have its CEO, Dr. Allan Reine, participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The event will be held in Miami Beach, FL, and will be accessible via a live audio webcast. Prime Medicine focuses on developing one-time curative genetic therapies using its proprietary Prime Editing platform.
Read more →PRMEPrime Medicine to Present at Jefferies Global Healthcare Conference
Prime Medicine, Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026. The CEO, Allan Reine, will participate in a fireside chat that will be accessible via a live audio webcast. Prime Medicine focuses on one-time curative genetic therapies developed through its Prime Editing platform, aiming to address various genetic mutations and diseases. The company has a diversified portfolio targeting liver, lung, immunology, and oncology conditions, with plans for future expansions into additional therapeutic areas.
Read more →PRME▼ -8.7%on this news
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. reported its financial results for Q1 2026, highlighting progress in its gene editing pipeline. The company is on track to file regulatory applications for PM577 and PM647, with initial clinical data expected in 2027. Despite a net loss of $49.1 million, Prime Medicine remains focused on advancing its therapies and has strengthened its leadership team.
Read more →PRMEPrime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Medicine has appointed Svetlana Makhni as Chief Financial Officer, effective immediately. Makhni will manage the company's financial operations and strategy, leveraging her extensive experience in biotechnology and investment banking. The CEO expressed confidence in her ability to position the company for success as it advances its therapeutic programs for Wilson Disease and Alpha-1 Antitrypsin Deficiency.
Read more →PRME▼ -9.2%on this news
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Medicine reported its financial results for 2025, highlighting a strong cash position of $191 million and plans to file IND and CTA for Wilson Disease and AATD programs in 2026. The company is also progressing towards submitting a BLA for PM359 following positive clinical data. Despite an increased net loss and R&D expenses, Prime Medicine remains focused on advancing its gene editing platform and delivering transformative therapies.
Read more →PRME▲ +7.8%on this news· ran to +22% by day 3
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc. announced its participation in three upcoming investor conferences. The company focuses on developing one-time curative genetic therapies using its proprietary Prime Editing platform. This technology aims to provide precise gene editing capabilities, potentially addressing numerous genetic conditions. The company is also working on a diversified portfolio of therapeutic programs in key areas such as liver, lung, and oncology.
Read more →PRME▲ +9.2%on this news
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
Prime Medicine, Inc. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Allan Reine will discuss the company's advancements in gene editing therapies, particularly its proprietary Prime Editing platform. The presentation will be available via a live audio webcast, with a replay accessible for 90 days post-event.
Read more →PRME▲ +12.6%on this news
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
Prime Medicine announced the publication of Phase 1/2 clinical data for PM359, an investigational treatment for chronic granulomatous disease (CGD), in the New England Journal of Medicine. The data showed promising results in two patients, including rapid engraftment and restoration of activity. The findings support the potential of Prime Editing as a safe and effective therapy for CGD.
Read more →PRMEPrime Medicine to Present at 8th Annual Evercore Healthcare Conference
Prime Medicine, Inc. will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025. CEO Allan Reine will participate in a fireside chat, focusing on the company’s advancements in gene editing therapies. Prime Medicine is utilizing its proprietary Prime Editing platform to develop innovative one-time curative genetic therapies, targeting a range of diseases across liver, lung, immunology, and oncology. The conference presentation highlights the company's commitment to advancing its research and development in genetic therapies.
Read more →PRMECORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine reported its third quarter 2025 financial results, highlighting advancements in its pipeline, including new preclinical data for PM577 in Wilson's Disease and the nomination of PM647 for Alpha-1 Antitrypsin Deficiency. The company plans to file INDs for both programs in 2026, with initial clinical data expected in 2027. Additionally, Matthew Hawryluk has been appointed as Chief Business Officer to strengthen the leadership team.
Read more →PRME▼ -8.9%on this newsshared move
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine reported its third quarter 2025 financial results, highlighting progress in its pipeline, including new data for PM577 in Wilson's Disease and the nomination of PM647 for Alpha-1 Antitrypsin Deficiency. The company is on track to file INDs for both programs in 2026 and expects initial clinical data in 2027. Additionally, they appointed a new Chief Business Officer to strengthen their leadership.
Read more →PRME▼ -7.7%on this news
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
Prime Medicine has appointed Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer. He will oversee corporate strategy and business development to enhance Prime Editing's reach through partnerships. Dr. Hawryluk brings nearly two decades of experience in biotechnology, having previously led significant collaborations and financing efforts. His leadership is expected to advance Prime Medicine's mission to deliver curative genetic therapies.
Read more →PRME▲ +13.6%on this newsshared move
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
Prime Medicine, Inc. announced a virtual event on November 12, 2025, to discuss its strategy for Wilson's Disease and its liver disease franchise. The company plans to file an IND for PM577, a treatment for H1069Q-driven Wilson's Disease, in the first half of 2026, with initial clinical data expected in 2027. The event will feature presentations from management and a leading expert in liver medicine.
Read more →PRME▼ -9.6%on this news
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates -- Announced positive data from two patients in Phase 1 2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinic
Prime Medicine announced its second quarter financial results for 2025, highlighting promising clinical data from a Phase 1/2 trial for Chronic Granulomatous Disease (CGD). The company raised $144.2 million through a public offering and secured additional funding from the Cystic Fibrosis Foundation, reflecting strong investor confidence. Leadership transitions accompanied by a strategic restructuring aim to improve operational efficiency while advancing programs for genetic diseases. However, Prime Medicine's current plans do not include independently advancing the CGD program.
Read more →PRME▲ +11.4%on this newsshared move
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Prime Medicine, Inc. has successfully closed its public offering of 43.7 million shares, raising approximately $144.2 million. The offering included the full exercise of the underwriters' option to purchase an additional 5.7 million shares. The shares were sold at a price of $3.30 each, with no commissions on shares sold to the Cystic Fibrosis Foundation.
Read more →PRMEPrime Medicine Announces Pricing of Public Offering
Prime Medicine, Inc. has announced the pricing of a public offering of 38 million shares at $3.30 each, aiming to raise approximately $125.4 million. The offering includes a 30-day option for underwriters to purchase additional shares. The company plans to use the proceeds to further its gene editing therapies, which target various diseases.
Read more →PRMEPrime Medicine Announces Proposed Public Offering of Common Stock
Prime Medicine, Inc. has initiated an underwritten public offering of its common stock, which includes an option for underwriters to purchase an additional 15% of shares. The offering is dependent on market conditions and lacks guarantees regarding its completion or specific terms. Prime Medicine focuses on developing advanced gene editing therapies and has a robust pipeline for therapeutic programs in various disease areas.
Read more →PRME▼ -5.8%on this news
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
Prime Medicine has announced an additional funding agreement with the Cystic Fibrosis Foundation, providing up to $24 million to enhance development of Prime Editing therapies for cystic fibrosis. This funding builds on a prior agreement from January 2024 and aims to leverage Prime Editing's versatility to target multiple mutations. The initial focus will be on addressing the G542X mutation, which currently has no available treatments. This partnership reflects the CF Foundation's commitment to innovative solutions for cystic fibrosis patients.
Read more →PRME▼ -16%on this news· ran to -26% by day 1
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
Prime Medicine has announced a strategic restructuring to focus on large genetic liver diseases, including Wilson's Disease and Alpha-1 Antitrypsin Deficiency. The company is poised to file for investigational new drug applications in 2026, with initial clinical data expected in 2027. Following initial positive data from a trial of PM359, Prime Medicine's leadership is transitioning with Allan Reine appointed as CEO. The restructuring also includes cost-cutting measures that will reduce its workforce by 25%, leading to a significant decrease in operating expenses.
Read more →PRME▼ -16%on this news· ran to -26% by day 1
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease First ever clinical data s
Prime Medicine announced favorable results from its Phase 1/2 trial of PM359, reporting rapid engraftment and restoration of NADPH oxidase activity in patients with Chronic Granulomatous Disease (CGD). Initial assessments indicate that 58% of patients showed DHR positivity by Day 15 and 66% by Day 30, surpassing expectations for clinical benefit. The safety profile appears acceptable, with no serious adverse events linked to the treatment. The company plans to explore external development options for PM359 as it shifts its focus toward advancing its in vivo liver franchise.
Read more →PRME▼ -7%on this news
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates -- Initial data from Phase 1 2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and or CTA for PM577 for Wilson's Diseas
Prime Medicine reported its financial results for Q1 2025, indicating a net loss of $51.9 million. The company is on track to provide initial data from its Phase 1/2 trial of PM359 for chronic granulomatous disease (CGD) in 2025, alongside progressing its programs for Wilson's Disease and alpha-1 antitrypsin deficiency (AATD). The company anticipates filing investigational new drug applications for both PM577 and AATD by mid-2026, demonstrating its commitment to advancing curative genetic therapies. However, concerns arise as cash reserves have decreased notably, indicating potential financial pressure in the coming years.
Read more →PRME▼ -15.3%on this newsshared move
PrimeMale Under Review: The 100% Natural Testo Booster for Best Libido Enhancement
PrimeMale is highlighted as a natural testosterone booster aimed at men over 30 experiencing symptoms of low testosterone such as reduced libido and energy. The article outlines how PrimeMale contains a blend of natural ingredients designed to support hormonal balance and improve vitality. While promoting its benefits, the article emphasizes the importance of consulting healthcare professionals before beginning any supplement regimen. It also addresses the contributing factors to declining testosterone levels in modern life.
Read more →PRME▼ -6.5%on this news· ran to -21% by day 3shared move
PrimeBiome: The Doctor-Endorsed Skin-Gut Gummies Backed by Science for Women
PrimeBiome is a doctor-endorsed daily gummy supplement aimed at improving women's skin and gut health. The product addresses common issues such as bloating, fatigue, hormonal breakouts, and mood swings, which are often linked to an imbalanced gut microbiome. Featuring a blend of prebiotics, probiotics, and plant-based compounds, PrimeBiome provides an integrative approach to women's wellness. It emphasizes a clean, effective formulation tailored to the physiological needs of women.
Read more →PRMEPrime Biome (I’ve Tested It for 90 Days) Here’s My Honest Prime Biome Gummies Review And Shocking Results! (Good, Bad & Real)
Prime Biome is a newly developed herbal skin supplement that aims to improve skin and gut health through a scientifically formulated blend of probiotics and plant extracts. A personal reviewer tested the product for 90 days and reported positive results, including reduced wrinkles and improved skin elasticity. While most user feedback has been favorable, there are concerns about mild side effects experienced by some users at the beginning of their usage. Overall, the product appears to be well-received with tangible benefits according to many customer testimonials.
Read more →PRME▲ +21.6%on this news
PrimeBiome Reviews: “Gut–Skin Miracle” or Just Hype? Expert Insights
The article discusses PrimeBiome, a dual-action probiotic gummy supplement that is gaining popularity for its potential benefits on gut health and skin rejuvenation. With over 19,000 customer reviews, the product promises enhancements in digestion, weight management, and skin clarity. It contains a unique blend of probiotics, prebiotics, and herbal ingredients, aiming to promote a holistic approach to wellness. The review will analyze user feedback, ingredient effectiveness, and whether PrimeBiome is a legitimate health solution or merely a marketing trend.
Read more →PRME▲ +21.6%on this news
Prime Biome Reviews 2025: Updated Comprehensive Guide to the Revolutionary Gut & Skin Health Supplement!
Prime Biome has gained popularity as a top probiotic supplement aimed at improving gut and skin health. Users have reported significant benefits, including reduced bloating, enhanced digestion, and healthier skin, leading to a high satisfaction rating of 4.9 out of 5. The supplement boasts a unique formulation that includes Bacillus coagulans along with prebiotics and adaptogens, providing a comprehensive approach to wellness. Additionally, Prime Biome assures quality with non-GMO ingredients and a 60-day money-back guarantee, making it a compelling choice for health-conscious consumers.
Read more →PRME▲ +12.1%on this news· ran to +41% by day 3shared move
Prime Biome Reviews (2025) Investigative Consumer Complaints Report Examines Scientific Claims About Gut-Skin PrimeBiome Gummies
Prime Biome is a new supplement targeting both gut health and skin clarity, utilizing the gut-skin axis concept. The gummies promise improvements in digestive issues and skin conditions like acne and eczema. With rising consumer interest in holistic health solutions, the product has become a topic of discussion across wellness platforms. An investigative report has been published to analyze its scientific claims and user experiences.
Read more →PRME▲ +12.1%on this news· ran to +41% by day 3shared move
Prime Biome Reviews: “Gut–Skin Miracle” or Just Hype? A Renowned Dermatologist Weighs In
Prime Biome is a probiotic supplement developed by dermatologist Dr. Jessica Argie, aimed at enhancing skin health through gut health. The product claims to rejuvenate skin by targeting the gut-skin axis, offering benefits such as improved complexion and digestion. While user testimonials highlight positive results, the product's effectiveness may vary by individual, and it should not be seen as a replacement for conventional medicine.
Read more →PRME▲ +12.1%on this news· ran to +41% by day 3shared move
PRIME BIOME GUMMIES Latest Study 2025, Read Before Buying
Prime Biome is a dietary supplement aiming to enhance gut health and overall wellness through a unique blend of probiotics and natural ingredients. The gummies are designed to promote the gut-skin connection, potentially improving skin health from within. Despite its promising approach, skepticism exists regarding its efficacy compared to traditional probiotics. Consumers are encouraged to consider individual responses to the product before use.
Read more →PRME▲ +12.1%on this news· ran to +41% by day 3shared move
PrimeBiome Reviews: MUST READ - Shocking Results - Ingredients & It's Benefits
Primebiome is a delicious gummy supplement aimed at improving gut health through a blend of probiotics and prebiotics. Users have reported benefits such as smoother digestion and clearer skin. The product is made in a cGMP-certified facility with non-GMO, vegan-friendly ingredients. It also comes with a 60-day money-back guarantee, allowing customers to try it risk-free.
Read more →PRME▼ -6.1%on this news· ran to +28% by day 3shared move
Prime Biome (Updated 2025): A Comprehensive Review of the Groundbreaking Skin-Gut Axis Supplement
Prime Biome is an innovative probiotic gummy supplement aimed at enhancing gut and skin health. Developed by dermatologist Dr. Jessica Burgy, it leverages the gut-skin axis for concurrent benefits. The supplement is manufactured under strict GMP guidelines, ensuring its quality and safety. Users are finding success with its dual-action approach, reporting improvements in digestive issues and skin conditions alike. With a 60-day money-back guarantee, the company emphasizes user confidence in its efficacy.
Read more →PRMEPrimeBiome Reviewed: Top 5 Reasons Why Prime Biome is the Best Option Available
The article reviews PrimeBiome, a probiotic supplement designed to address digestive and skin health through a dual-action approach. It highlights the growing recognition of PrimeBiome as a leading probiotic supplement in 2025, emphasizing its unique formulation that includes a range of beneficial probiotics, herbal adaptogens, and prebiotics. Research indicates that PrimeBiome effectively restores balance to the gut microbiome while simultaneously supporting skin vitality, making it an attractive option for individuals facing digestive discomfort and skin challenges. The article provides detailed insights on the formulation, real user experiences, and the science behind its effectiveness.
Read more →PRME▲ +8.7%on this newsshared move
Prime Biome Reviews (ALERT): I TRIED IT, Tracked It, and Exposed the Good, Bad & Unexpected
The article presents a personal review of Prime Biome, a probiotic supplement promising benefits for both digestion and skin health. The reviewer documented their 90-day trial, highlighting substantial improvements in digestion, skin clarity, and weight management. Key ingredients linked to the product's effectiveness include Bacillus coagulans and various herbal extracts. Overall, the review suggests that Prime Biome effectively addresses multiple health concerns through its unique gut-skin synergy formula.
Read more →PRME▲ +8.7%on this newsshared move
Prime Biome: We Tested It for 90 Days—Here’s the Real Month-by-Month Review, Unexpected Benefits, and the Science Backing It All
The article details a 90-day personal trial of Prime Biome, a probiotic designed to enhance gut and skin health. The reviewer experienced promising results, including reduced bloating, increased energy, and clearer skin, highlighting the potential benefits of the gut-skin connection. Overall, the review is positive, citing specific ingredients and their beneficial effects on overall well-being. It emphasizes that the product delivered tangible results, supporting the claims made by the brand.
Read more →PRME▼ -7.8%on this news· ran to -18% by day 1shared move
Prime Biome Reviews (SHOCKING RESEARCH EXPOSED): Does This Gut-Skin Link Actually Hold Up in 2025?
Prime Biome, a probiotic supplement, is gaining attention in 2025 for its dual focus on gut health and skin improvement. With a blend of clinically-proven ingredients, it claims to target the gut-skin axis, potentially transforming both digestion and skin appearance. Numerous user testimonials highlight visible results such as reduced bloating and clearer skin, contributing to the growing market demand. However, skepticism continues regarding the validity of these claims and whether they are substantiated by robust scientific evidence.
Read more →PRME▼ -7.8%on this news· ran to -18% by day 1shared move
Prime Biome Debuts Skin-Gut Cell Turnover Breakthrough with Essential Probiotics
Prime Biome has launched a revolutionary probiotic supplement designed to enhance both skin and gut health. The product combines a proprietary blend of probiotics, prebiotics, and natural ingredients, all packed into vegan-friendly gummy form. It claims to promote healthy skin cell turnover and support digestive balance. Consumer feedback has been largely positive, indicating improvements in digestive comfort and skin clarity. The supplement is available through the official website with a satisfaction guarantee.
Read more →PRME▼ -10.1%on this news· ran to -36% by day 3shared move
Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!
The article provides a detailed review of Prime Biome, a probiotic supplement aimed at improving both gut and skin health. After a 117-day trial period, the reviewer shares positive outcomes such as reduced bloating and improved skin complexion. The product's dual-action approach and scientifically backed ingredients are highlighted as key benefits. User testimonials further support its effectiveness in addressing common gut and skin issues.
Read more →PRMEPrime Biome Reviews DON’T SKIP UNTIL SEE THIS for Preventing Fraud and Guaranteeing Reliability!
Prime Biome is a supplement designed to improve gut and skin health through natural ingredients and probiotics. Marketed as effective for various skin issues, it aims to reduce inflammation and enhance digestion. The product is presented in a convenient gummy format and claims to promote overall wellness by balancing the microbiome. With a focus on quality, it is manufactured in FDA-inspected facilities and offers different pricing options for consumers.
Read more →PRME▼ -10.3%on this news· ran to -29% by day 3shared move
Prime Biome (INVESTIGATIVE REPORT): Does This Trending Gut Reset Supplement Actually Deliver Real Results?
The article discusses Prime Biome, a newly trending probiotic supplement aimed at improving gut health and skin rejuvenation. Marketed as a comprehensive solution to aging, it targets gut imbalance and inflammation through its unique formulation, which includes probiotics and prebiotic fibers. Early reviews from users indicate significant improvements in digestion and skin conditions. The product's claim of supporting anti-aging through gut health is positioned against a backdrop of skepticism due to the saturated wellness market.
Read more →PRMEPrime Biome Reviews (CONSUMER WARNING): Experts Reveal What Most People Miss About Probiotic Gummies
Prime Biome is a probiotic supplement designed to enhance gut health and skin vitality through a targeted formulation. Supported by health professionals, it utilizes advanced probiotics and anti-aging botanical extracts to promote cellular regeneration and microbiome balance. Clinical evidence suggests it may effectively improve skin conditions and digestion by utilizing resilient probiotic strains that survive stomach acid. The product is gaining attention as a comprehensive wellness solution in the health and beauty industry.
Read more →PRMEPrime Biome (REVIEW INVESTIGATION): Gut & Skin Health Supplement Put Under Medical Microscope
Prime Biome, a gut and skin health supplement, is under investigation amid rising popularity and mixed reviews about its safety and efficacy. The product claims to support the gut-skin connection with a blend of scientifically proven ingredients. An investigative review aims to clarify misconceptions about side effects and effectiveness. Overall, Prime Biome is presented as a safe alternative to traditional probiotics, designed to optimize gastrointestinal and skin health without harsh chemicals.
Read more →PRMEPrime Biome Gummies (EXPOSED): What Real Users Just Revealed About Prime Biome’s Gut & Skin Reset Formula
Prime Biome is a next-generation probiotic supplement aimed at rejuvenating the gut-skin connection through a unique formulation. It claims to address issues related to gut balance, nutrient absorption, and inflammation, potentially offering significant benefits for both digestion and skin health. Early user reviews are largely positive, with many reporting improvements in digestive comfort and skin clarity shortly after starting the product. However, some experts remain skeptical, questioning the validity of the bold claims made by the company, considering the saturated market of similar health products.
Read more →PRMEPrime Biome Reviews (SHOCKING TRUTH): What 67,000 Buyers Just Revealed About Side Effects & Gut Health
Prime Biome has gained recognition in the health and beauty industry for its potential benefits in gut and skin health, particularly through its formulation that targets the gut-skin axis. Experts, including dermatologists and functional medicine practitioners, endorse its unique blend of resilient probiotics and natural botanicals that enhance digestion and skin rejuvenation. Customer testimonials report significant improvements in various health aspects, including reduced bloating, clearer skin, and enhanced energy levels. The product is positioned as a scientific breakthrough in holistic wellness solutions for 2025.
Read more →PRMEPrime Biome Reviews (Is It Legit And Safe Ingredients?) Can This Probiotic Really Transform Your Skin And Gut?
Prime Biome is a probiotic supplement aimed at enhancing skin and gut health through natural ingredients. The formulation includes a blend of herbs and essential bacteria, which the manufacturers claim can address the root causes of skin aging linked to gut health. It is produced in the USA under stringent safety standards and comes in the form of easy-to-consume gummies. Customer feedback has been predominantly positive, attributing various health benefits, although individual results may vary.
Read more →PRMEPrime Biome Reviews (EXPOSED) Doctor Breaks Down Whether These Gummies Truly Support Aging, Gut Health & Full-Body Wellness
Prime Biome has emerged as a notable probiotic supplement that targets gut health and skin rejuvenation through its unique formulation. Backed by emerging research, it claims to improve digestion, nutrient absorption, and reduce signs of aging by balancing gut microbiota. Many users have reported positive experiences, particularly regarding reduced bloating and clearer skin. The product positions itself as a long-term investment in health rather than a quick fix.
Read more →PRMEPrime Biome Reviews: A Comprehensive Review of the Revolutionary Skin and Gut Health Supplement
Prime Biome, a probiotic supplement, offers dual benefits for skin and gut health, leveraging modern research to enhance overall wellness. It utilizes a unique formula that addresses digestive issues while promoting skin rejuvenation. Positive feedback from users illustrates notable improvements in skin clarity and digestive function. The product is manufactured in FDA-approved facilities, ensuring safety and efficacy in its ingredients.
Read more →PRMEPrime Biome Reviews (2025): Investigative Report Examines Whether This Gut-Skin Formula Is Scientifically Proven
Prime Biome, a probiotic gummy gaining popularity in 2025, claims to enhance both gut health and skin appearance through its unique formulation targeting the gut-skin axis. It boasts a powerful blend of probiotics and botanicals, backed by user testimonials and clinical studies. While many users report significant improvements in their skin and digestive health, some skepticism remains regarding the scientific backing and long-term effectiveness of the product. This investigative report aims to unpack these claims and provide a clearer understanding of Prime Biome's impact on gut and skin health.
Read more →PRMEPrime Biome Gummies Exposed (Clinical Analysis): Is This Probiotic Formula Really a Game-Changer for Beauty & Health?
The article analyzes the Prime Biome Gummies, a probiotic supplement designed for gut and skin health. It highlights the innovative formulation that includes Bacillus Coagulans and various botanicals, which are claimed to support digestion, skin elasticity, and metabolic health. Medical professionals are increasingly recognizing the potential of Prime Biome in holistic wellness, especially its effectiveness in improving skin vitality linked to gut health. However, it raises questions regarding the long-term benefits and variability of individual results.
Read more →PRMEDelivering on the promise of Prime Editing Corporate Presentation March 2025 1 Forward Looking Statements This presentation contains forward-looking statements of Prime Medicine, Inc. ( Prime , we or our ) within the mea
Prime Medicine, Inc. presented an overview of its forward-looking statements regarding the potential impact of Prime Editing technology on treating genetic diseases. The company highlighted advancements in its ongoing clinical trials for conditions such as chronic granulomatous disease (CGD), Wilson's disease, and Alpha-1 antitrypsin deficiency (AATD). Prime Medicine emphasized its strategy to achieve clinical validation and the importance of strategic collaborations to enhance its research and development efforts. Notably, the company claimed a differentiated safety profile, with no off-target activity observed in its lead programs.
Read more →PRMEPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Prime Medicine has introduced a new preclinical program to address alpha-1 antitrypsin deficiency (AATD), utilizing its proprietary prime editing technology aimed at restoring normal protein levels. The company reported promising results from preclinical studies, demonstrating high levels of gene editing with nearly 72% precision in correcting the disease-causing mutation. Prime Medicine plans to file an Investigational New Drug (IND) application in mid-2026, reflecting its commitment to advancing treatments for AATD and further exploring the capabilities of its technology in clinical settings.
Read more →PRMEPrime Biome Reviews And Complaints: A Detailed Study Released That’s Needs to Be Adopted for Which Type of Peoples?
Prime Biome is a probiotic supplement designed to enhance gut and skin health through a blend of beneficial ingredients. Developed by dermatologist Dr. Jessica Burgy, it targets the gut-skin axis to improve digestion and promote skin regeneration. Users report positive outcomes like improved skin clarity and digestion, though consultation with healthcare providers is recommended. The product is manufactured under strict guidelines ensuring quality and safety.
Read more →PRMEPrime Biome Reviews (Consumer Report Analysis) Safe Ingredients For Skin And Gut Health or Side Effect Complaints?
Prime Biome is a probiotic supplement designed to promote skin and gut health through its unique blend of natural ingredients. The formula includes clinically proven components such as Bacillus coagulans and Babchi, which support digestive health and skin rejuvenation. Manufactured in FDA-approved facilities, the supplement has gained a positive customer rating, reportedly showing no side effects. It is recommended for individuals looking to improve their skin's vibrancy and overall wellbeing.
Read more →PRMEPrime Biome Under Review: The Truth About Prime Biome and Microbiome Synergy for Gut & Skin Health
Prime Biome is a new supplement in gummy form that aims to improve gut health and skin vitality through a unique blend of probiotics and botanicals. Developed by dermatologist Dr. Jessica Burgy, this innovative product emphasizes the connection between gut health and skin conditions, proposing that beauty begins from within. Unlike conventional skincare, Prime Biome focuses on nurturing the gut microbiome to enhance overall wellness and support cellular turnover for a youthful complexion. The supplement is designed to appeal to a diverse demographic, addressing common aging and gut issues across different age groups.
Read more →PRMEPrime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
Prime Medicine reported its financial results for the full year 2024, showing a net loss of $195.9 million. The company is advancing key programs including PM359 for chronic granulomatous disease and PM577 for Wilson's Disease, with expectations for initial clinical data in 2025 and an IND filing in 2026. There are ongoing investigations into additional high-value programs, and Prime Medicine remains optimistic about its pipeline, despite facing increased R&D costs.
Read more →PRMEPrime Medicine to Present at TD Cowen 45th Annual Health Care Conference
Prime Medicine, Inc. will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025. Keith Gottesdiener, M.D., the CEO, will participate in a fireside chat during the event. The company focuses on creating advanced gene editing therapies using its proprietary Prime Editing platform, which aims to correct genetic mutations effectively across various diseases.
Read more →PRMEPrime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference
Prime Medicine, Inc. announced that CEO Keith Gottesdiener will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will outline the company's advancements in gene editing technology, specifically its proprietary Prime Editing platform. This technology aims to deliver one-time curative therapies targeting a range of diseases, with potential applications across various therapeutic areas. The live audio webcast of the event will be accessible through their website, with a replay available for 30 days.
Read more →PRMEPrime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
Prime Medicine, Inc. has reported its financial results for Q3 2024, showcasing significant advancements including a collaboration with Bristol Myers Squibb worth up to $3.5 billion. The company also presented initial in vivo data from its Wilson's Disease program, suggesting promising results in correcting genetic mutations. Furthermore, Prime Medicine is on track to file an IND and/or CTA in the first half of 2026. Despite an increase in net losses and administrative expenses, the company expects to have sufficient cash to fund its operations through mid-2026.
Read more →PRME▲ +5.3%on this news
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
Prime Medicine has shared positive interim preclinical data from its Wilson's Disease program, showcasing effective delivery of Prime Editors using a universal liver-targeted lipid nanoparticle (LNP). The results highlight significant correction of disease-causing mutations in both mouse and non-human primate models. The company is on track to initiate IND-enabling activities by the end of 2024, aiming for IND or CTA filing in the first half of 2026, with potential implications for other liver diseases as well.
Read more →PRMEPrime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
Prime Medicine, Inc. has announced it will present new preclinical data at upcoming scientific meetings, focusing on its Wilson's Disease program. The company aims to initiate IND-enabling activities by the fourth quarter of 2024, with a potential filing expected in the first half of 2026. Key presentations will include significant advancements in its Prime Editing technology and its applications in liver disease. The presentations will occur at the European Society of Gene and Cell Therapy and the American Association for the Study of Liver Diseases.
Read more →PRME▲ +11.8%on this news
Prime Medicine Unveils Strategically Focused Pipeline
Prime Medicine has announced a strategic focus on a streamlined pipeline prioritizing high-value genetic therapies. This includes a partnership with Bristol Myers Squibb to develop multiple Prime Edited T-cell therapies, paired with significant funding to extend operational cash runway into mid-2026. The company is set to share initial clinical data for its PM359 program in 2025 while advancing other targeted programs like those for Wilson’s Disease and Cystic Fibrosis. Regulatory support from the FDA adds optimism regarding the success of their modular gene editing approaches.
Read more →PRME▲ +11.8%on this news
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
Prime Medicine has entered into a strategic research collaboration and license agreement with Bristol Myers Squibb to develop ex vivo T-cell therapies. This partnership includes an initial payment of $110 million and potential milestones exceeding $3.5 billion, focusing on optimizing Prime Editor reagents. Through this collaboration, Prime Medicine aims to expand the application of its PASSIGE technology beyond rare genetic diseases to address significant unmet needs in immunological diseases and cancer. Both companies are optimistic about the revolutionary potential of Prime Editing in cell therapy.
Read more →PRMEPrime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
Prime Medicine, Inc. has reported its financial results for Q2 2024, highlighting significant advancements in its gene editing technology. The company has received FDA clearance to progress PM359 into clinical trials for chronic granulomatous disease, marking a pivotal moment in its growth. Additionally, Prime Medicine announced the promotion of Dr. Mohammed Asmal to Chief Medical Officer. Despite these developments, the company reported an increased net loss compared to the previous year, reflecting ongoing expenses while preparing for clinical product launches.
Read more →PRMEPrime Medicine to Present at Upcoming Investor Conferences
Prime Medicine, Inc. announced that its CEO, Dr. Keith Gottesdiener, will present at two significant investor conferences in June 2024. The presentations will take place at the Jefferies Healthcare Conference and the Goldman Sachs Global Healthcare Conference, with live webcasts available on the company's website. Prime Medicine focuses on innovative gene editing therapies using its proprietary Prime Editing platform, aiming to tackle various genetic diseases and possibly expand its therapeutic reach in the future.
Read more →PRME▲ +14.4%on this news· ran to +25% by day 3
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Prime Medicine, Inc. (Nasdaq: PRME) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. Allan Reine, M.D., CFO, will engage in a fireside chat during the event in New York. The presentation will be available via live audio webcast and a replay will be accessible for 90 days post-event. Prime Medicine focuses on developing one-time curative genetic therapies using its innovative Prime Editing platform.
Read more →PRMEPrime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
Prime Medicine, Inc. announced an FDA clearance for its first IND application for PM359, a gene therapy aimed at chronic granulomatous disease (CGD). The company anticipates initiating a Phase 1/2 clinical trial in the U.S. with initial data expected in 2025. Additional preclinical data presented at recent scientific meetings showcase the safety and potential of their Prime Editing technology. The company experienced a net loss of $45.8 million in the first quarter of 2024, despite an increase in cash reserves to $224.2 million.
Read more →PRMEPrime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
Prime Medicine has presented preclinical data for PM359, demonstrating its capability to correct a mutation linked to chronic granulomatous disease (CGD). The findings were shared during the American Society of Cell & Gene Therapy Meeting, highlighting restored immune function in edited blood stem cells. The U.S. FDA has recently cleared the investigational new drug application for PM359, which is set to advance into Phase 1/2 clinical trials, with first-in-human data expected in 2025. PM359 represents a significant step forward in targeting CGD and showcases the potential of Prime Editing technology.
Read more →PRME▲ +7.1%on this news
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
Prime Medicine, Inc. will participate in the upcoming 27th Annual Milken Institute Global Conference, where CEO Keith Gottesdiener will discuss groundbreaking innovations in gene editing. The conference is set for May 5-8, 2024, in Los Angeles, California. This event will enable Prime Medicine to showcase its advanced Prime Editing platform and its potential to revolutionize treatment for genetic diseases. A livestream of the panel will be available for those unable to attend in person.
Read more →PRME▲ +9.8%on this news· ran to +27% by day 3shared move
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine has received FDA clearance for its Investigational New Drug application for PM359, aimed at treating chronic granulomatous disease (CGD). This represents a significant milestone as it is the first IND clearance for a Prime Editing technology product. The upcoming Phase 1/2 clinical trial will assess the safety and effectiveness of PM359 in treating CGD. Initial clinical data is expected to be reported in 2025, showcasing the potential of this gene editing therapy.
Read more →PRMEPrime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
Prime Medicine, a biotechnology company, announced its upcoming presentations of preclinical data on Prime Editing technology at several scientific meetings in May 2024. The company is set to advance its program PM359 for chronic granulomatous disease (CGD) into clinical development next year, with results expected in 2025. Additionally, David Liu, a co-founder, received the ASGCT Outstanding Achievement Award, underscoring his contributions to gene editing. The presentations aim to showcase the effectiveness and safety of their Prime Editors, demonstrating the technology's potential across various genetic diseases.
Read more →PRMEPrime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
Prime Medicine, Inc. has reported its financial results for the year 2023, revealing a significant increase in net loss and a reduction in cash reserves. The company is poised for transformation into a clinical-stage entity, aiming to file an IND application for its PM359 therapeutic in early 2024. It is also advancing its gene-editing technology in collaborations, including with the Cystic Fibrosis Foundation. Upcoming milestones include launching IND-enabling activities for multiple disease programs and initiating their first clinical trials.
Read more →PRME▼ -5.1%on this news
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Prime Medicine, Inc. has completed an upsized public offering of 22,560,001 shares of its common stock at a price of $6.25 per share. The offering raised around $161 million, which will enhance the company's funding for developing innovative gene editing therapies. Additionally, the full exercise of the underwriters' option to purchase more shares signals robust interest in Prime Medicine's growth potential.
Read more →PRME▲ +13.6%on this news· ran to +24% by day 3shared move
Prime Medicine Announces Pricing of Upsized Public Offering
Prime Medicine, Inc. has announced the pricing of an upsized public offering of 19,200,001 shares at $6.25 per share, expected to close on February 20, 2024. This offering aims to raise approximately $140.0 million before deductions, showcasing heightened interest in the biotechnology sector. The proceeds will support the company's efforts in developing differentiated one-time curative genetic therapies using their proprietary Prime Editing platform. However, the offering's success hinges on satisfactory market conditions and customary closing requirements.
Read more →PRME▲ +5.7%on this news
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Prime Medicine, Inc. will be presenting at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. CEO Keith Gottesdiener will engage in a fireside chat discussing the company's innovative approach to genetic therapies. Prime Medicine focuses on developing one-time curative genetic therapies using its proprietary Prime Editing technology, aimed at addressing unmet medical needs. The company is progressing with a portfolio of eighteen programs targeting genetic diseases, showcasing its commitment to advancing gene editing options.
Read more →PRMEPrime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
Prime Medicine has secured up to $15 million from the Cystic Fibrosis Foundation to advance its Prime Editing technology aimed at treating cystic fibrosis (CF). The funding will support two strategies, hotspot editing and PASSIGE, to correct genetic mutations linked with CF. Preclinical findings indicate that a few Prime Editors could address mutations affecting a vast majority of CF patients, including those with rare mutations. This partnership underscores a significant step towards potentially offering a one-time, curative genetic therapy for CF.
Read more →PRMEDelivering on the promise of Prime Editing JP Morgan Healthcare Conference January 2024 1 Forward Looking Statements This presentation contains forward-looking statements of Prime Medicine, Inc. ( Prime , we or our ) wit
Prime Medicine, Inc. recently presented forward-looking statements at the JP Morgan Healthcare Conference regarding its Prime Editing technology. The presentation outlined the company's strategic goals, including the initiation of clinical trials, potential regulatory filings, and collaboration with Cimeio to integrate technologies for treating diseases. Prime Medicine aims to provide curative genetic therapies across various diseases and is on track to achieve significant milestones in 2024.
Read more →PRMEPrime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
Prime Medicine has appointed Allan Reine, M.D., as its Chief Financial Officer, effective January 17, 2024. Dr. Reine, with over twenty years of experience in the biotechnology sector, is expected to drive the company's financing strategy and manage investor relations as it transitions into a clinical entity. His expertise includes a strong financial and operational background, which Prime Medicine hopes to leverage to advance its lead programs and expand its innovative genetic therapies. The company focuses on addressing a range of diseases using its cutting-edge Prime Editing technology.
Read more →PRMEPrime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
Prime Medicine, Inc. will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The presentation will be led by Keith Gottesdiener, M.D., the President and CEO of the company. Prime Medicine is noted for its innovative Prime Editing technology, which aims to develop one-time curative genetic therapies for various diseases. The company currently has a portfolio of eighteen programs focused on genetic diseases with significant unmet medical needs.
Read more →PRME▲ +17.6%on this newsshared move
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
Prime Medicine, Inc. reported its financial results for the third quarter of 2023, highlighting advancements in its Prime Editing platform. The company showcased promising preclinical data and received Rare Pediatric Drug designation for PM359 aimed at treating Chronic Granulomatous Disease. Prime Medicine also expanded its intellectual property with a new patent and demonstrated a strong safety profile in initial studies. However, notable increases in R&D and G&A expenses were reported, reflecting ongoing investment in research and development activities.
Read more →PRME▼ -6.6%on this news
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
Prime Medicine reported positive preclinical data for its Prime Editing technology, demonstrating its capability to precisely correct the GSD1b mutation in non-human primates with up to 83% efficiency. This breakthrough suggests potential therapeutic advancements for GSD1b, a serious genetic disorder affecting glycogen metabolism. The study revealed no off-target effects, underscoring the editor's precision. These findings were presented at the ESGCT 2023 Congress, highlighting the promise of Prime Editing for future applications in genetic diseases.
Read more →PRMEPrime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
Prime Medicine presented new data on their Prime Editing technology at RD2023, showcasing its potential to correct mutations causing rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP). The studies revealed up to 70% correction in humanized mouse models without off-target edits or significant adverse effects. The findings are significant for the treatment of RHO adRP, which currently has no approved therapies. The results underline the promise of Prime Editing technology to improve outcomes for a large population of affected patients.
Read more →PRME▲ +10%on this news
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
Prime Medicine, Inc. is set to present significant advancements in its Prime Editing pipeline during various upcoming healthcare conferences. The company highlights new preclinical data showcasing the potential of its genetic therapies, specifically proof-of-concept results from rodent and larger animal studies. CEO Keith Gottesdiener emphasized the progress across their portfolio, suggesting it reinforces the promise of Prime Editing for treating genetic disorders. Presentations include topics on developing prime editors for specific diseases and efficiency in correcting genetic mutations.
Read more →PRME▼ -8.7%on this news
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
Prime Medicine reported its second quarter 2023 financial results, emphasizing advancements in its Prime Editing technology and strategic partnerships. Key highlights include promising data for PM359 in correcting mutations related to chronic granulomatous disease (CGD) and a collaboration with Cimeio Therapeutics to enhance treatment options. The company also noted a net loss of $42.4 million for the quarter, alongside a strong cash position that supports its operations into 2025. Upcoming milestones include IND-enabling studies and further preclinical data releases expected later this year.
Read more →PRMEPrime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
Prime Medicine and Cimeio Therapeutics have announced a collaboration focused on combining their innovative platforms to improve treatment options for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The partnership aims to enhance the safety and effectiveness of hematopoietic stem cell transplants by utilizing Cimeio's Shielded Cell and Immunotherapy Pairs technology alongside Prime Medicine's Prime Editing. The collaboration seeks to mitigate the risks associated with myeloablative conditioning regimens, potentially allowing for in vivo treatment of these diseases without the need for transplantation. If successful, this partnership could significantly expand therapeutic possibilities for patients facing debilitating conditions.
Read more →PRMEPrime Medicine to Present at Investor Conferences in June
Prime Medicine, a biotechnology company, has announced its participation in three investor conferences throughout June 2023. CEO Keith Gottesdiener will engage in discussions that highlight the company's innovative gene editing technologies and therapeutic developments. The conferences include the Jefferies Healthcare Conference and the Goldman Sachs Global Healthcare Conference, alongside a panel on in vivo cell therapy. This is part of Prime Medicine's strategy to showcase its advancements in addressing genetic diseases.
Read more →PRMEPrime Medicine to Present at Virtual Investor Conferences in May
Prime Medicine, a biotechnology company focused on gene editing therapies, announces that CEO Keith Gottesdiener will present at two virtual investor conferences in May 2023. The presentations will be held at the Barclays 2023 Gene Editing & Gene Therapy Summit and the Stifel 2023 Tailoring Genes: Genetic Medicines Day. The company aims to leverage its Prime Editing platform to develop precise and efficient genetic therapies, focusing on genetic diseases with high unmet needs.
Read more →PRMEPrime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
Prime Medicine presented new preclinical data at the ASGCT 26th Annual Meeting, showcasing the efficacy of its Prime Editing technology in correcting mutations associated with chronic granulomatous disease (CGD) and utilizing its PASSIGE platform for CAR-T cell generation. The data highlighted significant advancements in promising gene-editing approaches, particularly with the potential to create durable treatments for CGD and enhance CAR-T cell effectiveness. Overall, the findings could propel the development candidates forward, highlighting Prime Medicine's commitment to curative therapies.
Read more →PRME▼ -10.6%on this news
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
Prime Medicine, Inc. announced its financial results for Q1 2023, showcasing progress in its gene editing technology. The company aims to address chronic granulomatous disease through its Prime Editing platform, revealing promising preclinical data. Additionally, Prime Medicine appointed Jeff Marrazzo to its Board, further enhancing its leadership team. The company has extended its patent portfolio significantly, although it reported a net loss of $39.4 million amidst increased R&D and operational expenses.
Read more →PRME▲ +5.9%on this news
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
Prime Medicine, Inc. (Nasdaq: PRME) announced that its CEO, Dr. Keith Gottesdiener, will present a corporate overview at the Guggenheim Healthcare Talks focused on genomic medicines and rare diseases. The event is scheduled for April 3, 2023, in New York City. Prime Medicine specializes in differentiated one-time curative genetic therapies using their innovative Prime Editing technology, which has the potential to address a wide array of genetic mutations. The company aims to make significant advancements in the treatment of genetic diseases.
Read more →PRMEPrime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Announced preclinical data providing further proof-of-concept for Prime Editing s ability to achieve restoration of
Prime Medicine, Inc. released its fourth quarter and full year financial results for 2022, highlighting significant advancements in its Prime Editing technology. The company reported a successful IPO, raising $199 million, and announced new preclinical proof-of-concept data demonstrating the effectiveness of its editing platform with minimal off-target activity. Additionally, Prime Medicine has selected PM359 as its first development candidate for Chronic Granulomatous Disease, with plans to advance into investigational new drug studies later this year. The financial outlook indicates that funds are sufficient to cover operating expenses through 2025.
Read more →PRMEPrime Medicine to Present at Cowen 43rd Annual Health Care Conference
Prime Medicine, Inc. will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023. CEO Keith Gottesdiener will provide a corporate overview during the event. The company focuses on innovative genetic therapies using Prime Editing technology, which could potentially repair numerous genetic mutations. A live audio webcast of the presentation will be made available for attendees.
Read more →PRMEPrime Medicine st 41 Annual J.P. Morgan Healthcare Conference January 2023 1 Forward-Looking Statements This presentation contains forward-looking statements of Prime Medicine, Inc. ("Prime", "we" or "our") within the me
Prime Medicine presented at the 41st Annual J.P. Morgan Healthcare Conference in January 2023, sharing insights on its forward-looking strategies and the potential of its Prime Editing technology. The company aims to advance genetic therapies targeting various diseases, emphasizing the versatility and precision of its platform. With ongoing studies and multiple programs advancing toward development candidates, Prime Medicine anticipates its first investigational new drug filing as early as 2024. The presentation highlights the company's commitment to innovative therapeutic solutions in gene editing.
Read more →PRMEPrime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
Prime Medicine has reported significant advancements in its Prime Editing technology, including promising preclinical data demonstrating restoration of genetic function in conditions like Friedrich's ataxia and cystic fibrosis. Importantly, preliminary safety analyses showed no off-target activity in Prime Edited Wilson's disease cells. The company is also showcasing effective delivery methods for its technologies in vivo. As Prime Medicine moves into 2023, it outlines strategic priorities aimed at progressing its pipeline of eighteen programs toward clinical applications.
Read more →PRME▼ -5.6%on this news
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
Prime Medicine, Inc. announced that its CEO, Keith Gottesdiener, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is set for January 9, 2023, and will highlight the company's commitment to differentiated one-time curative genetic therapies using Prime Editing technology. This technology has the potential to correct a vast majority of disease-causing genetic mutations, paving the way for new treatment options.
Read more →PRMEPrime Medicine Announces Closing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its upsized initial public offering of 10,294
Read more →PRMEPrime Minister Roosevelt Skerrit presents $1.2 billion budget for Fiscal Year 2022-2023
Roseau, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The global market has witnessed several shocks over the last few years, but the Commonwealth of Dominica has been able to protect itself from these thanks to assistance of the Citizenship by Investment Programme. This year, the programme
Read more →PRMEPrime Blockchain Announces Proposed Reverse Takeover by RYAH
VERDUN, Qu bec and NEW YORK, June 27, 2019 (GLOBE NEWSWIRE) -- Prime Blockchain Inc. (“Prime Blockchain” or the “Company”) announced that it has entered into a binding letter of intent (the “LOI”) with Potbotics Inc. o/a RYAH (“RYAH”), a leading data aggregation and technology co
Read more →PRMEPRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA)
Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in children European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a m
Read more →PRMEPRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington's disease
European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting the underlying caus
Read more →PRMEPrime Venture Partners Raises INR 400 crore in Fund 3
BENGALURU, India, March 07, 2018 (GLOBE NEWSWIRE) -- Prime Venture Partners, an early stage fund, today announced the close of its third fund at INR 400 crore (~$60M). Prime will continue to focus on making concentrated investments with high conviction and support, maintaining it
Read more →Competitive Position
How PRME ranks across every disease it competes inCompetitive Position is a premium feature
See how PRME ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial